Fyzoclad (adalimumab)
- Region
- 🇪🇺 EU
- Active substance
- adalimumab
- Company
- Pfizer Europe MA EEIG
- Status
- Application withdrawn
- Therapeutic area
- Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid; Psoriasis; Arthritis, Psoriatic; Spondylitis, Ankylosing; Uveitis
- Application
- EMEA/H/C/005253
- ATC
- L04AB04
- Official record
- www.ema.europa.eu
Indication
Treatment of juvenile idiopathic arthritis, paediatric plaque psoriasis, paediatric uveitis
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Idacio Authorised · Fresenius Kabi Deutschland GmbH
- 🇪🇺 Humira Authorised · AbbVie Deutschland GmbH & Co. KG
- 🇪🇺 Yuflyma Authorised · Celltrion Healthcare Hungary Kft.
- 🇪🇺 Hulio Authorised · Biosimilar Collaborations Ireland Limited
- 🇪🇺 Amgevita Authorised · Amgen Europe B.V.
- 🇪🇺 Hukyndra Authorised · Stada Arzneimittel AG
- 🇪🇺 Libmyris Authorised · Stada Arzneimittel AG
- 🇪🇺 Hefiya Authorised · Sandoz GmbH
- 🇪🇺 Imraldi Authorised · Samsung Bioepis NL B.V.
- 🇪🇺 Hyrimoz Authorised · Sandoz GmbH
- 🇪🇺 Amsparity Authorised · Pfizer Europe MA EEIG
- 🇪🇺 Halimatoz Withdrawn · Sandoz GmbH
Follow Fyzoclad
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.